BCM
TEVA icon

BlueCrest Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

BlueCrest Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-110,000
Closed -$3.53M – 1098
2017
Q1 		$3.53M Sell
110,000
-40,000
-27% -$1.37M 0.17% 171
2016
Q4 		$5.44M Buy
150,000
+135,000
+900% +$5.39M 0.3% 102
2016
Q3 		$690K Buy
+15,000
New +$783K 0.02% 445

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlueCrest Capital Management's TEVA Position: Q2 2017 in Review

BlueCrest Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q2 2017, closing a stake of 148,084 shares — an estimated $4.75M sold.

BlueCrest Capital Management first reported a position in TEVA in Q1 2016 and held it in 3 quarters. The position peaked at $4.75M in Q1 2017. 649 funds tracked by Wall St. Rank hold TEVA as of Q2 2017.

  • BlueCrest Capital Management reported no remaining Teva Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • BlueCrest Capital Management sold 148,084 Teva Pharmaceuticals shares in Q2 2017, an estimated $4.75M.
  • BlueCrest Capital Management first reported a position in Teva Pharmaceuticals in Q1 2016 and held it in 3 quarters.
  • BlueCrest Capital Management's Teva Pharmaceuticals position peaked at $4.75M in Q1 2017.
  • 649 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2017.

Based on BlueCrest Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.